Chardan Capital Believes uniQure NV (QURE) Still Has Room to Grow

In a report released today, Gbola Amusa from Chardan Capital reiterated a Buy rating on uniQure NV (QURE), with a price target of $100. The company’s shares opened today at $59.53, close to its 52-week high of $60.61.

According to TipRanks.com, Amusa is a 5-star analyst with an average return of 16.9% and a 50.3% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.

uniQure NV has an analyst consensus of Strong Buy, with a price target consensus of $69.71, implying a 17.1% upside from current levels. In a report issued on February 25, Cantor Fitzgerald also reiterated a Buy rating on the stock with a $81 price target.

See today’s analyst top recommended stocks >>

Based on uniQure NV’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $22.04 million. In comparison, last year the company had a GAAP net loss of $27.47 million.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded on January 9, 2012 and is headquartered in Amsterdam, the Netherlands.